Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of GO306 Recombinant Oncolytic Vaccinia Virus Injection in Patients With Advanced Refractory Solid Tumors.
Conditions
Interventions
GO306
Locations
6
China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Shenzhen Third People's Hospital
Shenzhen, Guangzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Start Date
July 31, 2025
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2026
Last Updated
December 19, 2025
NCT07299747
NCT07231120
NCT07264803
NCT06883539
NCT07303387
NCT04668833
Lead Sponsor
GeneSail Biotech (Shanghai) Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions